Pan-caspase peptide inhibitor to induce primary chronic lymphocytic leukemia (CLL) cell death through a non-apoptotic and non-necroptotic mechanism.

Conatus’ pan-caspase inhibitor IDN-7314 was administered as a treatment to block caspase activation, resulting in reduced inflammasome activation and demonstrated beneficial effects on liver ...

Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration ...

C1 inhibitor protein is predominantly expressed in the liver, which has led to the suggestion that hereditary angioedema can be viewed as a metabolic liver disorder. 6 One group reported a case of ...

- SUDO-550 is a potential best-in-class, orally administered, brain-penetrant TYK2 inhibitor being developed for the treatment of neuroinflammatory diseases. - Phase 1 clinical trial supported by ...

Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only Werner helicase inhibitor to have made it into the clinic.

Pirtobrutinib is a selective, noncovalent (reversible) BTK inhibitor that inhibits both wild-type and C481-mutant BTK (the most common mutation associated with resistance to covalent BTK ...

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal cancer.

The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.

Scientists commonly use caspase assays to evaluate apoptosis, evaluating caspase activation—a hallmark of apoptosis initiation—with fluorescent dyes. Researchers often perform multiplex caspase assays ...